#PortfolioNews | Our #portfolio company Neurona Therapeutics plans Phase3 trial in H2 2025 for NRTX-1001, a #celltherapy for drug-resistant #epilepsy.

🔬 Encouraging early data: Up to 97% seizure reduction with no cognitive impairment

📢 Read more: https://buff.ly/3Dh9kfv

#VC